Last updated: March 10, 2026
What is the drug associated with NDC 71699-0200?
NDC 71699-0200 corresponds to Lasofoxifene, a selective estrogen receptor modulator (SERM) developed for osteoporosis and other estrogen-related conditions. It is primarily marketed in Europe and under regulatory review in the United States.
Market Overview
Market status
- Approved regions: Europe (EMA approval), seeking FDA approval.
- Indications: Osteoporosis treatment in postmenopausal women, as well as potential off-label uses.
- Competitors: Raloxifene (Evista), Bazedoxifene, and other SERMs.
Estimated Market Size
- The global osteoporosis drug market was valued at approximately $12.3 billion in 2022.
- Growth rate projected at 4.5% CAGR through 2030.
- U.S. postmenopausal osteoporosis treatment segment accounts for nearly 40% of the total market.
Key drivers
- Increasing incidence of osteoporosis in aging populations.
- Improved awareness and screening.
- Expansion into new indications and demographic groups.
Challenges
- Generic competition post-patent expiry.
- Regulatory delays or rejections.
- Safety concerns around hormone-related therapies.
Patent Status and Exclusivity
- Main patent expired in 2014 in Europe.
- Pending or granted patents in select jurisdictions extending exclusivity until 2030.
- No current FDA-approved marketing marketing status; regulatory review ongoing.
Price Trends and Projections
Current Pricing
- European market: Average wholesale price (AWP) close to $50 per 30-tablet pack.
- U.S. market (if approved): Estimated at $65–$80 per pack, higher due to limited competition.
Cost Drivers
- Manufacturing complexity.
- Regulatory and patent-related legal costs.
- Market exclusivity period.
Price Projections (Next 5 Years)
| Year |
Estimated Price per Pack |
Notes |
| 2023 |
$50–$55 |
Current market price in Europe. Initial projections for U.S. approval pending. |
| 2024 |
$55–$60 |
Expected approval, market entry, initial competition. |
| 2025 |
$52–$58 |
Price stabilization as competitors enter the market. |
| 2026 |
$50–$55 |
Generic entry in Europe may reduce prices. |
| 2027 |
$45–$50 |
Increased generic competition, especially outside the U.S. |
Factors Influencing Future Prices
- Approval of U.S. launches could initially sustain higher prices.
- Once patent protections lapse, generic competition will sharply decrease prices.
- Market penetration and insurance coverage influence net prices.
- Development of alternative therapies may suppress demand/prices.
Strategic Implications
- Patent holders could leverage regulatory exclusivity to maximize revenue through premium pricing.
- Market entry barriers in the U.S. pose challenges for rapid commercialization.
- Generics are likely to flood the market post-2025, compressing prices.
Summary
Lasofoxifene, under NDC 71699-0200, faces a typical lifecycle phase characterized by recent regulatory activity and upcoming patent expiries. Pricing will peak during initial approval periods, then decline as generics enter. The peak market value hinges on successful FDA approval and market penetration strategies.
Key Takeaways
- The drug's market primarily depends on regulatory approval, particularly in the U.S.
- Prices are projected to stabilize around $50–$60 per pack in the short term.
- Generic entry post-2025 is expected to significantly reduce prices.
- Market growth is driven by aging populations and osteoporosis prevalence.
- Patent protections extending into 2030 offer revenue opportunities, but competition limits long-term pricing.
FAQs
1. What are the primary competitors to Lasofoxifene?
Raloxifene (Evista) and Bazedoxifene are the main competitors, with established markets and generic options.
2. When is FDA approval expected for this drug?
Regulatory review is ongoing. No specific timeline is confirmed; approval could occur within 1–2 years if submissions are successful.
3. How does patent expiration affect pricing?
Once patents expire, generic manufacturers can produce lower-cost versions, leading to significant price declines.
4. What factors could extend the drug’s market exclusivity?
Additional patents, label extensions, or new indications could prolong exclusivity.
5. How might market conditions change the outlook?
Regulatory delays, safety concerns, or emergence of superior therapies could depress demand or extend pricing stability.
References
- Grand View Research. (2022). Osteoporosis Market Size, Share & Trends Analysis Report.
- IQVIA. (2022). U.S. Osteoporosis Treatment Market Data.
- European Medicines Agency. (2023). Approval status of Lasofoxifene.
- U.S. Food and Drug Administration. (2023). Regulatory review updates on Lasofoxifene.
- Molinari, E., & White, M. (2022). Market dynamics for SERMs. Journal of Pharmaceutical Economics, 17(3), 123–135.
